In vitro and in vivo oxidative metabolism and glucuronidation of anastrozole.
about
New approach to analyze genetic and clinical data in bisphosphonate-induced osteonecrosis of the jaw.Genetic factors affecting gene transcription and catalytic activity of UDP-glucuronosyltransferases in human liverBlack cohosh and breast cancer: a systematic review.An unusual cause of jaundice in a patient with breast cancer.Estrogens and their precursors in postmenopausal women with early breast cancer receiving anastrozole.CYP1A2--a novel genetic marker for early aromatase inhibitor response in the treatment of breast cancer patientsCYP2D6 metabolism and patient outcome in the Austrian Breast and Colorectal Cancer Study Group trial (ABCSG) 8.Effect of MRP2 and MRP3 Polymorphisms on Anastrozole Glucuronidation and MRP2 and MRP3 Gene Expression in Normal Liver Samples.Potential role of UGT1A4 promoter SNPs in anastrozole pharmacogenomicsSelective induction of tumor cell apoptosis by a novel P450-mediated reactive oxygen species (ROS) inducer methyl 3-(4-nitrophenyl) propiolate.CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients.Fulvestrant decreases anastrozole drug concentrations when taken concurrently by patients with metastatic breast cancer treated on SWOG study S0226.Fulvestrant up regulates UGT1A4 and MRPs through ERα and c-Myb pathways: a possible primary drug disposition mechanism.Preclinical discovery of candidate genes to guide pharmacogenetics during phase I development: the example of the novel anticancer agent ABT-751.Pharmacogenomics of third-generation aromatase inhibitors.Impact of metabolizing enzymes on drug response of endocrine therapy in breast cancer.Transcriptional regulation of human UDP-glucuronosyltransferase genes.Role of Cytochrome P450 2C8 in Drug Metabolism and Interactions.Germline genetic predictors of aromatase inhibitor concentrations, estrogen suppression and drug efficacy and toxicity in breast cancer patients.Evaluation of a New Molecular Entity as a Victim of Metabolic Drug-Drug Interactions-an Industry Perspective.The implications of genetic variation for the pharmacokinetics and pharmacodynamics of aromatase inhibitors.Molecular basis of aromatase inhibitor associated arthralgia: known and potential candidate genes and associated biomarkers.Use of anastrozole in the chemoprevention and treatment of breast cancer: A literature review.In vitro glucuronidation of aprepitant: a moderate inhibitor of UGT2B7.The use of aromatase inhibitors in boys with short stature: what to know before prescribing?Complementary and alternative medicines use by Scottish women with breast cancer. What, why and the potential for drug interactions?In vitro evaluation of the inhibition and induction potential of olaparib, a potent poly(ADP-ribose) polymerase inhibitor, on cytochrome P450.Metabolism of the hepatotoxic compound sophoraflavanone G in rat liver microsomes.Polymorphisms in ABCB1 and CYP19A1 genes affect anastrozole plasma concentrations and clinical outcomes in postmenopausal breast cancer patients.Glucuronidation: driving factors and their impact on glucuronide dispositionResearch HighlightsEffects of psoralen on the pharmacokinetics of anastrozole in rats
P2860
Q34160379-D983E5F2-22A4-40DE-B6AB-7047D0A2A94BQ34211851-66FDBF0A-AF71-492D-8D29-F4049D219233Q34601209-E6C86545-1274-454B-81AD-B6FEE94C7877Q34799879-52815D5E-5EC8-48E6-82A1-7238B2A716B7Q35118969-D7A4BE1B-7A78-445A-BEF6-9FF3129C19ECQ35974459-8308BFC2-6697-4269-9FAC-1BC58100F320Q36545056-59BDB0A0-C3E3-4908-823C-2F73DB86930FQ36684423-665ECA6E-5624-4AB4-98B7-47C0A6DD77B2Q36717159-61C93ED1-E5C0-4C06-9E1D-83CBF0CB5962Q36724891-EBD25762-086A-4CAC-B2E3-E09942E8AFC1Q36727678-54D9EFFA-78B1-4707-BB4D-19BC745A7FB8Q36924682-1C1B85F3-7DF7-4BD7-BD65-2D2D0F550E72Q37344821-C10BE268-1331-4A62-B92D-2E2126B9B34EQ37382760-BE779C6E-A39A-4FC6-A037-66E18EBB4168Q38010777-2B82D8B1-53E4-465E-BB39-BEAAF285336EQ38103593-5E562A6A-91E4-482B-8C95-E182CFF335D5Q38261875-471C157E-E19F-44D0-A531-77A4FF0B7406Q38684505-77B90ED0-4EAF-4559-B403-60F384D63D1EQ38739248-8CF91DAE-2F41-4576-B952-30A0420041F5Q38800092-7AD0A712-6763-4CED-A10D-8F195A3DB6D9Q38851505-562A1FB0-A773-4897-9905-D34843D5B763Q38956073-CCB4E7DB-4407-4BE3-B7D4-988D6857D1E0Q39373643-69D4195B-70DC-4E51-8DBC-8EC1B23C776AQ40600601-5E43DC32-BBCA-4197-A455-07F4F8F68F73Q47700487-9746DBEB-7C7B-4F7E-91F9-08CB58ED8381Q50520737-2EA61429-F113-4730-86A0-6CBEFA43FD49Q50557160-E7588BDC-D506-41CD-B9DA-DA12B31132ABQ51081578-E29A9C12-EA01-4C53-ABA5-BD19EAD829E2Q51387487-FD91A615-963F-428E-852F-2D2841350CB4Q56030213-9B7B365B-084B-4740-A7AF-E7672E65E351Q57585715-47D328BD-E239-4EA8-A31B-A4FF730B82E8Q57785680-0BE92737-20A9-4744-9DE9-B09701A2466D
P2860
In vitro and in vivo oxidative metabolism and glucuronidation of anastrozole.
description
2010 nî lūn-bûn
@nan
2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
In vitro and in vivo oxidative metabolism and glucuronidation of anastrozole.
@ast
In vitro and in vivo oxidative metabolism and glucuronidation of anastrozole.
@en
In vitro and in vivo oxidative metabolism and glucuronidation of anastrozole.
@nl
type
label
In vitro and in vivo oxidative metabolism and glucuronidation of anastrozole.
@ast
In vitro and in vivo oxidative metabolism and glucuronidation of anastrozole.
@en
In vitro and in vivo oxidative metabolism and glucuronidation of anastrozole.
@nl
prefLabel
In vitro and in vivo oxidative metabolism and glucuronidation of anastrozole.
@ast
In vitro and in vivo oxidative metabolism and glucuronidation of anastrozole.
@en
In vitro and in vivo oxidative metabolism and glucuronidation of anastrozole.
@nl
P2093
P2860
P50
P1476
In vitro and in vivo oxidative metabolism and glucuronidation of anastrozole.
@en
P2093
Bryan A Ward
Evan Ogburn
Jacqueline Ramirez
Karineh Shahverdi
Landry K Kamdem
Stacie Jeter
Susan A Kadlubar
P2860
P304
P356
10.1111/J.1365-2125.2010.03791.X
P407
P577
2010-12-01T00:00:00Z